JP2017195897A5 - - Google Patents

Download PDF

Info

Publication number
JP2017195897A5
JP2017195897A5 JP2017134066A JP2017134066A JP2017195897A5 JP 2017195897 A5 JP2017195897 A5 JP 2017195897A5 JP 2017134066 A JP2017134066 A JP 2017134066A JP 2017134066 A JP2017134066 A JP 2017134066A JP 2017195897 A5 JP2017195897 A5 JP 2017195897A5
Authority
JP
Japan
Prior art keywords
mmv
virus
tcid
less
protein concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017134066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017195897A (ja
JP6522054B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017195897A publication Critical patent/JP2017195897A/ja
Publication of JP2017195897A5 publication Critical patent/JP2017195897A5/ja
Application granted granted Critical
Publication of JP6522054B2 publication Critical patent/JP6522054B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017134066A 2010-04-14 2017-07-07 高力価、高純度のウイルスストックの作製方法及びその使用方法 Expired - Fee Related JP6522054B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32422010P 2010-04-14 2010-04-14
US61/324,220 2010-04-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015081173A Division JP6284500B2 (ja) 2010-04-14 2015-04-10 高力価、高純度のウイルスストックの作製方法及びその使用方法

Publications (3)

Publication Number Publication Date
JP2017195897A JP2017195897A (ja) 2017-11-02
JP2017195897A5 true JP2017195897A5 (https=) 2017-12-14
JP6522054B2 JP6522054B2 (ja) 2019-05-29

Family

ID=44148425

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013504963A Pending JP2013523175A (ja) 2010-04-14 2011-04-08 高力価、高純度のウイルスストックの作製方法及びその使用方法
JP2015081173A Expired - Fee Related JP6284500B2 (ja) 2010-04-14 2015-04-10 高力価、高純度のウイルスストックの作製方法及びその使用方法
JP2017134066A Expired - Fee Related JP6522054B2 (ja) 2010-04-14 2017-07-07 高力価、高純度のウイルスストックの作製方法及びその使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013504963A Pending JP2013523175A (ja) 2010-04-14 2011-04-08 高力価、高純度のウイルスストックの作製方法及びその使用方法
JP2015081173A Expired - Fee Related JP6284500B2 (ja) 2010-04-14 2015-04-10 高力価、高純度のウイルスストックの作製方法及びその使用方法

Country Status (9)

Country Link
US (1) US9644187B2 (https=)
EP (1) EP2377927B1 (https=)
JP (3) JP2013523175A (https=)
KR (1) KR101549296B1 (https=)
CN (1) CN102985536B (https=)
BR (1) BR112012026095A2 (https=)
ES (1) ES2736166T3 (https=)
SG (1) SG184833A1 (https=)
WO (1) WO2011130119A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
SG11201405185PA (en) * 2012-03-13 2014-10-30 Emd Millipore Corp Use of centrifugation-aided infection to increase virus titer
US9809800B2 (en) 2012-11-22 2017-11-07 Asahi Kasei Medical Co., Ltd. Method for producing parvovirus having high infectivity titer
EP2958995A4 (en) * 2013-02-22 2016-11-23 Agency Science Tech & Res CHROMATOGRAPHIC CLEANING OF VIRUS PREPARATIONS WITH NEGATIVELY LOADED PARTICLES
US9632087B2 (en) * 2013-09-10 2017-04-25 MockV Solutions Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles
EP3372677B8 (en) * 2015-11-06 2019-09-25 Asahi Kasei Medical Co., Ltd. Method for producing parvovirus having high infectivity titer and high purity
DE102016005049B4 (de) 2016-04-26 2020-06-18 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung des logarithmischen Reduktionswertes LRV eines Größenausschlussfilters
EP3299454A1 (en) * 2016-09-21 2018-03-28 Deutsches Krebsforschungszentrum Optimized method for large scale production of parvovirus h-1 in an essentially serum-free medium
EP3141611A3 (en) * 2016-10-21 2017-05-10 Bayer Healthcare LLC Validation of continuous viral clearance
US10961512B2 (en) * 2017-04-17 2021-03-30 Dao-Yao He Compositions and kits for purification of viral particles from host cells
KR102453351B1 (ko) 2017-07-05 2022-10-07 에스케이바이오사이언스(주) 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법
EP3446710A1 (en) * 2017-08-25 2019-02-27 Glenmark Pharmaceuticals S.A. Methods of inactivating viral contaminants
CN108841794B (zh) * 2018-06-08 2021-11-30 苏州良辰生物医药科技有限公司 一种病毒原液的制备方法
JP7588466B2 (ja) * 2020-01-22 2024-11-22 旭化成メディカル株式会社 パルボウイルスの生産方法
US20230103302A1 (en) * 2020-02-28 2023-04-06 Asahi Kasei Medical Co., Ltd. Method for evaluating viral clearance capability
WO2021261451A1 (ja) * 2020-06-24 2021-12-30 旭化成メディカル株式会社 タンパク質含有溶液の評価方法
CA3195893A1 (en) * 2020-09-21 2022-03-24 Bayer Healthcare Llc Pathogen clearance system and method
US12203914B2 (en) 2020-11-12 2025-01-21 Sartorius Bioanalytical Instruments, Inc. Viral clearance evaluation for biological medical product preparation processes
JP7612001B2 (ja) 2021-03-26 2025-01-10 旭化成メディカル株式会社 ウイルスクリアランス試験の方法
WO2022252098A1 (zh) * 2021-05-31 2022-12-08 中国科学院深圳先进技术研究院 噬菌体制剂的制备方法、药物组合物以及应用
JP7665143B2 (ja) * 2021-06-24 2025-04-21 株式会社島津製作所 ウイルス試料の濃縮方法
WO2026055296A2 (en) * 2024-09-06 2026-03-12 Amgen Inc. Production of viral stocks

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622663A (en) 1968-06-13 1971-11-23 American Home Prod Purification of viruses on treated calcium dihydrogen orthophosphate monohydrate adsorbent
US3919044A (en) 1973-03-28 1975-11-11 Armour Pharma Processes for concentrating and purifying viruses and viral antigens
SU579309A1 (ru) 1973-11-16 1977-11-05 Ленинградский Политехнический Институт Им.М.И.Калинина Способ получени вакцины
FR2475572A1 (fr) 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
JPS6147185A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6147186A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147187A (ja) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
US7115363B1 (en) 1986-01-22 2006-10-03 Institut Pasteur Retrovirus capable of causing AIDS, means and methods for detecting it in vitro
US5824482A (en) 1986-06-23 1998-10-20 Institut Pasteur Purification, cloning, and characterization of a novel human immunodeficiency virus LAVMAL
US4814268A (en) 1986-10-06 1989-03-21 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US4859597A (en) * 1987-07-27 1989-08-22 Igene Biotechnology, Inc. Production of phage and phage-associated lysin
NZ225583A (en) 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5268292A (en) 1988-06-27 1993-12-07 Robertson Betty H Reproducible generation of high yields of hepatitis A virus by cell culture
GB8914968D0 (en) 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US5719051A (en) 1989-12-22 1998-02-17 Immuno Aktiengesellschaft Perfusion system and a method for the large scale production of virus or virus antigen
DE4003543A1 (de) 1990-02-06 1991-08-08 Orpegen Med Molekularbioforsch Verfahren zur abreicherung von viren in loesungen und zur bestimmung der abreicherungsrate von viren
US6709811B1 (en) 1990-05-24 2004-03-23 The United States Of America As Represented By The Department Of Health And Human Services Versatile reagent for detecting murine leukemia viruses
DK0494317T4 (da) 1990-06-15 2001-04-02 Innogenetics Nv SIV cpz-ant-retrovirus og anvendelse deraf
IT1248075B (it) 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5658779A (en) 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
ATE174382T1 (de) 1992-10-06 1998-12-15 Dade Behring Marburg Gmbh Retrovirus aus der hiv-gruppe und dessen verwendung
DE69515028T2 (de) 1994-03-22 2000-06-29 The Immune Response Corp., Carlsbad Die hocheffiziente herstellung und isolierung von viruspartikeln
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
DE69534166T2 (de) 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
US5756341A (en) 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
WO1997008298A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
KR100461701B1 (ko) 1996-02-29 2005-04-06 다카라 바이오 가부시키가이샤 바이러스의정제및제거방법
KR20000005120A (ko) 1996-03-29 2000-01-25 스칸드레트 존 디 파라폭스바이러스 벡터
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
ZA982950B (en) 1997-04-08 1998-10-19 Merck & Co Inc Stabilized human papillomavirus formulations
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
US6037456A (en) 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
US5994134A (en) 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
HUP0103091A3 (en) 1998-08-14 2002-03-28 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
AU5689699A (en) 1998-08-24 2000-03-14 Uab Research Foundation Methods of producing high titer recombinant adeno-associated virus
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
CN1087032C (zh) 1998-12-14 2002-07-03 彭朝晖 一种生产重组腺病毒的方法
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
NZ512504A (en) * 1998-12-31 2004-01-30 Aventis Pharma Sa Method for separating viral particles
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
US6316185B1 (en) 1999-09-29 2001-11-13 Mountain View Pharmaceuticals, Inc. Quantitation of viruses by light scattering
WO2001040448A1 (en) 1999-12-02 2001-06-07 The General Hospital Corporation Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
JP2003518380A (ja) 1999-12-29 2003-06-10 ジェンザイム・コーポレイション 核酸および他の細胞性汚染混入物質からウイルスベクターを分離するための濾過助剤の使用方法
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
AU2001285263A1 (en) 2000-08-25 2002-03-13 The General Hospital Corporation Selective precipitation of viruses
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US7195905B2 (en) 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
ATE386824T1 (de) 2002-03-29 2008-03-15 Merck & Co Inc Verfahren zur virusproduktion
EP1492890A4 (en) 2002-03-29 2006-10-18 Merck & Co Inc EXPLOSIVE PROCEDURE FOR THE PRODUCTION OF ADENOVIRUS AND ADENOVIRUS STEM MIXTURES
DE60327069D1 (de) 2002-04-30 2009-05-20 Oncolytics Biotech Inc Verbesserte reinigungsmethode für viren
ATE360683T1 (de) 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
WO2004000220A2 (en) 2002-06-21 2003-12-31 Genetix Pharmaceuticals, Inc. Methods for purifying viral particles for gene therapy
US20060228334A1 (en) * 2002-07-10 2006-10-12 Manuel Rosa-Calatrava Modified adenoviral fiber with ablated to cellular receptors
ES2305514T5 (es) 2002-09-05 2019-06-14 Bavarian Nordic As Método para la amplificación de un poxvirus en condiciones exentas de suero
US20050009168A1 (en) 2003-05-12 2005-01-13 Robbins Joan Marie Methods and apparatus for Adeno associated virus purification
EP1633321A4 (en) 2003-06-18 2006-11-02 Onyx Pharma Inc METHOD FOR CLEANING VIRUS
AU2003272868A1 (en) 2003-10-15 2005-04-27 Agtc Gene Technology Company Ltd. Method for large-scale production, isolation, purification and the uses of multi-type recombinant adeno-associated virus vectors
EP1697505A1 (en) 2003-12-23 2006-09-06 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
JP2007537760A (ja) 2004-05-20 2007-12-27 アイディー バイオメディカル コーポレイション インフルエンザワクチンを製造するためのプロセス
BRPI0511764B8 (pt) 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
DE102004049290A1 (de) 2004-10-09 2006-04-20 Bayer Healthcare Ag Verfahren zur Herstellung von Virusmaterial
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
AU2005305347A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
US20060281075A1 (en) 2004-12-22 2006-12-14 Large Scale Biology Corporation Purification of viruses, proteins and nucleic acids
US7344839B2 (en) 2004-12-23 2008-03-18 Aurx, Inc. Virus preparations and methods
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
DE102005047301B4 (de) 2005-09-30 2009-04-16 Sartorius Stedim Biotech Gmbh Verfahren zum Nachweis der Virenabreicherung für die Validierung von Filtern und Filtrationsprozessen
US20070172846A1 (en) 2005-11-12 2007-07-26 Introgen Therapeutics, Inc. Methods for the Production and Purification of Adenoviral Vectors
US7754421B2 (en) 2005-11-18 2010-07-13 National Research Council Of Canada Detection of intact recombinant viruses
KR101157176B1 (ko) 2005-12-20 2012-06-20 삼성전자주식회사 세포 또는 바이러스의 농축 또는 정제용 미세유동장치 및방법
EP2018421B1 (en) * 2006-04-28 2012-12-19 The Trustees of the University of Pennsylvania Scalable production method for aav
US7851196B2 (en) 2006-05-01 2010-12-14 The Regents Of The University Of California Methods for purifying adeno-associated virus particles
CN101516395B (zh) * 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
JP2010512748A (ja) 2006-12-15 2010-04-30 シェーリング−プラウ・リミテッド インフルエンザウイルスを培養物中で複製するための方法
US20080299545A1 (en) * 2007-03-06 2008-12-04 Shuyuan Zhang Chromatographic methods for assessing adenovirus purity
WO2008113011A2 (en) * 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
EP2134757A2 (en) 2007-03-27 2009-12-23 University of Maryland, College Park Imprinted polymeric materials for binding various targets such as viruses
CN104694489A (zh) 2007-05-04 2015-06-10 巴克斯特国际公司 用于病毒纯化用连续超速离心的糖溶液配方
CN102257134B (zh) * 2008-02-12 2014-03-05 赛诺菲巴斯德有限公司 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
US9651469B1 (en) * 2016-01-27 2017-05-16 General Electric Company Electrostatic particle sensor

Similar Documents

Publication Publication Date Title
JP2017195897A5 (https=)
JP6720288B2 (ja) ウイルス用無菌精製プロセス
CN102078605B (zh) Vero细胞流感病毒疫苗制备方法
JP6730949B2 (ja) 生体高分子ユニットおよびウイルスを液体から分離するための方法
JP2012018171A5 (https=)
JP2013516429A5 (https=)
CN114471163B (zh) 二次两级切向流分离纯化和浓缩外泌体的超滤装置及方法
CN103073652A (zh) 一种螺旋藻多糖的提取方法
CN108118044A (zh) 一种分离提纯蛋清溶菌酶的方法
CN104404094A (zh) 基于蛤利用酶转化法提取牛磺酸的方法
Lothert et al. Evaluation of restricted access media for the purification of cell culture‐derived Orf viruses
CN104111314A (zh) 一种采用有序介孔炭识别水相中超滤膜污染物的方法
CN116463300A (zh) 一种犬细小病毒生产纯化工艺及应用
CN102191226A (zh) 细胞培养混合物的分离纯化方法
CN114106114A (zh) 利用离子交换层析纯化口蹄疫病毒抗原的方法
EP2603234B1 (en) Method for reducing dna impurities in viral compositions
CN110904276A (zh) 噬菌体在生物制品病毒清除工艺验证中的应用
CN114395539B (zh) 去除乙脑疫苗制品残留宿主dna和宿主蛋白的方法
CN117487769A (zh) 一种规模化鸡胚源病毒纯化方法及其应用
CN117625562A (zh) 一种提高疫苗纯度的方法、通过该方法得到的疫苗及其应用
Warnke et al. Evaluating the Filterability of Chemically Defined Cell Culture Media With the Virosart® Media Filter
CN103435670B (zh) 一种从肌苷母液中回收肌苷的方法
JPH01141593A (ja) ウロキナーゼの回収方法及びそれにより得られるウロキナーゼ含有画分
CN117603344A (zh) 一种鸡卵黄免疫球蛋白IgY的提取纯化方法
RU2021131851A (ru) Непрерывное получение рекомбинантных белков